share_log

Dawson James Initiates Coverage On Zomedica With Buy Rating, Announces Price Target of $6

Benzinga Real-time News ·  Jan 7, 2023 00:26

Dawson James analyst Jason Kolbert initiates coverage on Zomedica (AMEX:ZOM) with a Buy rating and announces Price Target of $6.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment